1. Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma 
Dean A. Fennell, PhD, FRCP, Cliona McDowell, PhD, Sara Busacca, PhD, Glen Webb, MSc, Brian Moulton, PhD, Andrew Cakana, FIBMS, FRCP, Kenneth J. O’Byrne, PhD, MD, Jan V. Meerbeeck, PhD, MD, Paul Donnellan, MB, FRCPI, John McCaffrey, MD, FRCPI, Paul Baas, PhD 
Journal of Thoracic Oncology 
Volume 7, Issue 9, Pages (September 2012)
DOI: /JTO.0b013e318260dfb9
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
A, Kaplan–Meier for disease progression—first line patients, median time to progression was 2.23 months (95% confidence limits 1.15–4.76). B, Kaplan–Meier for overall survival—first line patients. Median overall survival was months (95% confidence limits 1.77–not applicable). C, Kaplan–Meier for disease progression—second line patients. Median time to progression was 2.1 months (95% confidence limits 1.84–2.07). D, Kaplan–Meier for overall survival—second line patients. Median overall survival was 5.78 months (95% confidence limits 3.12–9.43).
Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318260dfb9)
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Noxa expression measured by immunohistochemistry associated with mesothelioma archival diagnostic biopsies.
Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318260dfb9)
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions